Peptide Initiative

Peptides · Peptide comparison

CJC-1295 with DAC vs Ipamorelin

Long-acting growth hormone releaser that works around the clock to boost your body's natural GH production with just one or two injections per week.

A uniquely selective growth hormone booster that tells your pituitary to release more GH without messing with your cortisol or other hormones—making it the 'clean' choice among growth hormone peptides.

  • Growth Hormone
  • Growth Hormone

At a glance

Quick comparison

Dose rangeCJC-1295 with DAC2–2 mgIpamorelin200–200 mcg
FrequencyCJC-1295 with DACTwice weeklyIpamorelinMultiple times daily
AdministrationCJC-1295 with DACSubcutaneous injectionIpamorelinSubcutaneous injection
Cycle lengthCJC-1295 with DAC8-12 weeksIpamorelin8-12 weeks
Onset speedCJC-1295 with DACModerate (1-2 weeks)IpamorelinModerate (1-2 weeks)
Evidence levelCJC-1295 with DACModerate human trials (Phase 1-2)IpamorelinModerate human trials (Phase 1-2)

Efficacy

Benefit ratings

GH Elevation

CJC-1295 with DAC92%
IpamorelinNo recorded rating

Convenience

CJC-1295 with DAC95%
IpamorelinNo recorded rating

Recovery Support

CJC-1295 with DAC88%
Ipamorelin90%

GH Selectivity

CJC-1295 with DACNo recorded rating
Ipamorelin98%

Safety Profile

CJC-1295 with DACNo recorded rating
Ipamorelin92%

Technical data

Compound specifications

CJC-1295 with DAC

Molecular formula
C165H269N47O46
Molecular weight
3647.28 g/mol
Half-life
6-8 days
Bioavailability
~100% (subcutaneous)
CAS number
863288-34-0

Ipamorelin

Molecular formula
C38H49N9O5
Molecular weight
711.85 g/mol
Half-life
2 hours
Bioavailability
High when injected subcutaneously
CAS number
170851-70-4

Protocols

Dosing compared

CJC-1295 with DAC

Subcutaneous

  • 1 mg (1000 mcg)Once weekly · 2-4 weeksA starting dose used in practice. The DAC version is long-acting (about a 6-8 day half-life), so weekly dosing keeps growth hormone and IGF-1 raised. In the Phase 1 trial a single dose raised GH for 6+ days and IGF-1 for up to 11 days. [2]
  • 2 mg (2000 mcg)Once weekly (or split twice weekly) · 8-12 weeksThe common maintenance dose, roughly in line with the 30-60 mcg/kg weekly range studied in the Phase 1 trial. [1][2] In the ascending-dose trials, single injections raised mean GH 2- to 10-fold for six or more days and IGF-I 1.5- to 3-fold for 9-11 days; 30 and 60 µg/kg doses were the best tolerated [2].
  • 2 mg per doseTwice weekly · 8-12 weeksA higher total weekly amount split into two doses, used by experienced users; near the top of the 30-60 mcg/kg weekly range from the clinical study. [2]

Ipamorelin

Subcutaneous

  • 100 mcg per injection2-3 times daily · 4-8 weeksConservative entry dose; Ipamorelin is a selective GH secretagogue with a ~2 hour half-life, so doses are split through the day [1][2]. Used in research and practice to assess tolerance before titrating up.
  • 200 mcg per injection2-3 times daily · 8-12 weeksMost commonly cited research/practice dose; gives a meaningful pulsatile GH release without raising cortisol or prolactin at standard doses [1][2].
  • 300 mcg per injection3 times daily · 8-12 weeksUpper end of the commonly used range; total daily exposure split across three injections. Used in practice by experienced users [1].

Applications

Best suited for

CJC-1295 with DAC

Growth Hormone Optimization
CJC-1295 with DAC excels at providing a sustained, steady elevation of growth hormone levels. Unlike shorter-acting peptides that create brief spikes, the DAC modification keeps GH elevated for days, mimicking a more youthful hormone profile.
Muscle Building and Recovery
By increasing both GH and IGF-1 levels, this peptide supports protein synthesis and muscle repair. Users often notice improved recovery between workouts and better ability to build and maintain lean muscle mass.
Anti-Aging and Longevity
Growth hormone naturally declines with age, contributing to many signs of aging. CJC-1295 with DAC helps restore more youthful GH levels, potentially supporting better skin quality, energy levels, and overall vitality.
Body Composition Improvement
The combination of increased GH and IGF-1 promotes fat metabolism while preserving muscle tissue. Many users experience gradual fat loss, particularly in stubborn areas, while maintaining or building lean mass.
Convenient Weekly Dosing
Unlike peptides requiring daily or twice-daily injections, the extended half-life of CJC-1295 with DAC means just one or two injections per week provide continuous benefits. Ideal for those who want results without daily protocols.

Ipamorelin

Clean GH Boost Seekers
If you want the benefits of increased growth hormone without spiking cortisol or other stress hormones, Ipamorelin is uniquely selective. Unlike GHRP-2 or GHRP-6, it won't raise your cortisol levels even at doses 200 times higher than needed for GH release.
Recovery-Focused Athletes
Ipamorelin shines for athletes who want better recovery between training sessions. The GH boost helps repair muscle tissue faster, and since it doesn't mess with other hormones, you can use it consistently without the rollercoaster effects.
Anti-Aging Enthusiasts
Growth hormone naturally declines as we age, contributing to muscle loss, fat gain, and reduced vitality. Ipamorelin offers a gentle way to restore more youthful GH levels without the risks of actual HGH therapy.
Those Recovering from Steroid Use
Research shows Ipamorelin can help counteract the muscle and bone-weakening effects of glucocorticoid medications. If you've been on steroids for medical reasons, this peptide may help you rebuild what you've lost.

Safety profile

Side effects

CJC-1295 with DAC

Common

  • Injection site reactions
  • Water retention
  • Flushing
  • Tingling sensation

Uncommon

  • Headaches
  • Fatigue or lethargy
  • Joint discomfort

Serious

  • Carpal tunnel symptoms
  • Blood glucose elevation

Ipamorelin

Common

  • Mild headache
  • Injection site reactions
  • Water retention
  • Increased appetite

Uncommon

  • Tingling in hands or feet
  • Joint stiffness

Serious

  • Allergic reaction

Research status

Safety & evidence

CJC-1295 with DAC

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
CJC-1295 with DAC was evaluated in Phase 1-2 human clinical trials where it demonstrated a generally favorable safety profile. The most common adverse events were mild injection site reactions including temporary pain, swelling, and redness. No serious adverse events were reported in the published clinical studies. The compound was being developed for HIV-associated lipodystrophy before the program was discontinued.

Contraindications

  • Active cancer or history of malignancy
  • Pregnancy or breastfeeding
  • Pituitary tumors or disorders
  • Diabetic retinopathy
  • Uncontrolled diabetes

Ipamorelin

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Ipamorelin's main selling point is that it raises growth hormone without raising cortisol or ACTH — two stress hormones that similar peptides do raise. That was shown in pigs, and it held even at doses more than 200 times higher than the amount needed to raise growth hormone [1]. It has not been checked in people. The two published human studies measured ipamorelin and growth hormone only; neither one assayed cortisol, ACTH or prolactin [2][3]. Most of what we know about safety in people comes from a single trial in patients recovering from bowel surgery. 114 people took part: 56 got ipamorelin through an IV for up to seven days, and 58 got a placebo. Most side effects were mild to moderate, and were the kind you would expect after surgery [3]. Serious problems happened at about the same rate in both groups — roughly 1 in 6 either way (17.9% on ipamorelin, 15.5% on placebo). But three things were more common on ipamorelin: low potassium in about 1 in 8 people versus about 1 in 30 on placebo (12.5% vs 3.4%), trouble sleeping in about 1 in 9 versus about 1 in 19 (10.7% vs 5.2%), and high blood sugar at discharge in about 1 in 7 versus about 1 in 12 (14.3% vs 8.6%) [6]. Two people taking ipamorelin died. Both had colon cancer surgery, and in both cases the surgical join in the bowel leaked afterward. Nobody on the placebo died. The FDA says it is unclear whether those deaths had anything to do with ipamorelin — but it pointed to them, along with the potassium and blood sugar differences, when it recommended in October 2024 against letting pharmacies compound ipamorelin [6].

Contraindications

  • Active cancer or history of cancer
  • Pregnancy or breastfeeding
  • Pituitary disorders or tumors
  • Known allergy to peptide components
  • Children and adolescents (growth plates still open)

Decision guide

Which is right for you?

CJC-1295 with DAC

Choose CJC-1295 with DAC if…

  • Boosting natural growth hormone production
  • Building lean muscle mass
  • Improving body composition
  • Anti-aging and longevity

Ipamorelin

Choose Ipamorelin if…

  • Muscle recovery and growth
  • Anti-aging and vitality
  • Body composition improvement
  • Sleep quality enhancement